TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06058247

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active nutritional supplementation
Description: The participants in active nutritional supplementation arm received consultation from the nutritional support team (NST) upon ICU admission, and nutritional supplementation was initiated on the same day.~NST is a multidisciplinary support team comprised of physicians, nurses, dietitians, and pharmacists, which assesses the nutritional status of patients, and provides recommendations for nutritional therapy. Targets in the participants in active nutritional supplementation arm were protein supplementation at over 1.5 g/kg/day, calorie provision at over 20 kcal/kg/day, and energy adequacy of at least 80%. Energy target was estimated by multiplying the resting energy expenditure using the Harris and Benedict equation by an activity factor of 1.3 and a stress factor of 1.1. Actual body weight was used as the body weight for patients with a percent of ideal body weight (PIBW) of less than 120%, while adjusted body weight was used for patients with a PIBW greater than or equal to 120%.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conventional nutritional supplementation
Description: The participants in conventional nutritional supplementation arm received conservative nutritional management without specific protein or caloric targets.
Study: NCT04136327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 film-coated tablets
Description: single oral dose of GLPG1972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GLPG1972 solution for infusion
Description: a 15-minute IV infusion \[14C\]-GLPG1972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GLPG1972 oral solution
Description: single oral dose of \[14C\]-GLPG1972
Study: NCT01292356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Study: NCT03350958

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alginate Bread
Description: 100g Alginate Bread, toasted with 20g of butter.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alginate Bread
Description: 100g Alginate Bread, toasted with 20g of butter.
Study: NCT00609492

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)
Description: Single dose, intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)
Description: Single dose, intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)
Description: Single dose, intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™-IPV/Hib
Description: Single dose, intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™-IPV/Hib
Description: Single dose, intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™-IPV/Hib
Description: Single dose, intramuscular injection
Study: NCT01713972

Intervention type: DRUG
Group type: OTHER
Intervention: dabrafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib
Description: Given PO

Intervention type: DRUG
Group type: OTHER
Intervention: pazopanib hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: OTHER
Intervention: Correlative studies
Description: Pharmacokinetic studies:~Blood draw for various time points:~Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12~* Pharmacogenomic studies: Blood draw on Cycle 1 Day 1~* Tumor genotyping: Archival tumor blocks or unstained slides~* BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative studies
Description: Pharmacokinetic studies:~Blood draw for various time points:~Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12~* Pharmacogenomic studies: Blood draw on Cycle 1 Day 1~* Tumor genotyping: Archival tumor blocks or unstained slides~* BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression
Study: NCT02073500

Intervention type: OTHER
Intervention: Observational study.
Description: Analysis of metastatic tissue and blood specimens collected from patients with PSM undergoing CRS-HIPEC. CRS: Removal of all macroscopically detectable tumor.~HIPEC: Instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease.
Study: NCT06294249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser-induced Incision
Description: On the treatment side, an incision was made on the crest of the alveolar soft tissue using the laser.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Punch Incision
Description: On the control side, a punch incision was made on the crest of the alveolar soft tissue using using a punch.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant Placement
Description: Implant placement was done in both laser and punch arms. The drilling was performed based on the company (Straumman) protocol. On each side, a dental implant (Straumman SP, Basel, Switzerland) and healing abutment were placed. Patients were visited at 24, 48, 72 hours, and 7 days after insertion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant Placement
Description: Implant placement was done in both laser and punch arms. The drilling was performed based on the company (Straumman) protocol. On each side, a dental implant (Straumman SP, Basel, Switzerland) and healing abutment were placed. Patients were visited at 24, 48, 72 hours, and 7 days after insertion.
Study: NCT04504721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: light therapy
Description: The intervention will take 8 weeks with 30 minutes exposure at awakening to blue-enriched white light.
Study: NCT04111510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor infiltrating lymphocytes (TIL) LN-145
Description: The TIL autologous therapy with LN-145 is comprised of the following steps:~1. Tumor resection to provide the autologous tissue that serves as the source of the TIL cellular product;~2. LN-145 investigational product production at a central Good Manufacturing Practice (GMP) facility;~3. A 7-day nonmyeloablative lymphodepletion (NMA-LD) preconditioning regimen (hospitalization per institution standards);~4. Infusion of the autologous LN-145 product on Day 0 (during inpatient hospitalization);~5. Intravenous (IV) interleukin-2 (IL-2) administrations for up to six doses maximum (during inpatient hospitalization).
Study: NCT03350958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Bread
Description: 100g standard White Bread (control), toasted with 20g of butter.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Bread
Description: 100g standard White Bread (control), toasted with 20g of butter.
Study: NCT03653650

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRP plus BCL
Description: Bandage contact lens (BCL) plus 1 autologous platelet-rich plasma (PRP) eye drop every 1 to 3 hours.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: BCL plus PFL
Description: Bandage contact lens (BCL) plus 1 preservative-free lubricant (PFL) eye drop every 1 to 3 hours.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Eye patch plus ocular lubricant ointment
Description: Eye patch plus ocular lubricant ointment every 24 hours.
Study: NCT04324996

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells
Description: The CAR-NK cells are universal off the shelf NK cells enriched from umbilical cord blood and engineered genetically.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells
Description: The CAR-NK cells are universal off the shelf NK cells enriched from umbilical cord blood and engineered genetically.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells
Description: The CAR-NK cells are universal off the shelf NK cells enriched from umbilical cord blood and engineered genetically.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells
Description: The CAR-NK cells are universal off the shelf NK cells enriched from umbilical cord blood and engineered genetically.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells
Description: The CAR-NK cells are universal off the shelf NK cells enriched from umbilical cord blood and engineered genetically.
Study: NCT05031091

Intervention type: OTHER
Intervention: standardised exposure questionnaire
Description: A standardised exposure questionnaire will be conducted face to face or by telephone. The search for risk factors for leprosy and in particular direct or indirect contact with armadillos will be explored

Intervention type: OTHER
Intervention: standardised exposure questionnaire
Description: A standardised exposure questionnaire will be conducted face to face or by telephone. The search for risk factors for leprosy and in particular direct or indirect contact with armadillos will be explored
Study: NCT01180894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: 100 mg IV TIW

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02539173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound scan
Description: Non-invasive and non-irradiating. The diaphragmatic thickening in recovery is measured before and after the completion of the anesthetic block using the ultrasound system, the ultrasound probe and of an aqueous gel by trans-thoracic approach.~It measures the thickness on deep inspiration and expiration in supine position. Each measurement is repeated twice. This measurement series lasts 4 minutes, is repeated 15 minutes after completion of the engine block when a block is found and contralateral. The total measurement time is about 12 minutes.
Study: NCT03501004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sterile acupuncture needles for single use
Description: Sterile acupuncture needles for single use are made by China Beijing Zhongyan Taihe Medical Instrument Limited Company.Acupuncture needles' specifications are 0.25mm\*25mm.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sterile acupuncture needles for single use
Description: Sterile acupuncture needles for single use are made by China Beijing Zhongyan Taihe Medical Instrument Limited Company.Acupuncture needles' specifications are 0.25mm\*25mm.
Study: NCT03803670

Intervention type: DIAGNOSTIC_TEST
Intervention: evaluation of cerebrospinal fluid of ALL
Description: We evaluated cerebrospinal fluids of patients with ALL by conventional cytology and by flow cytometry
Study: NCT03666780

Intervention type: DEVICE
Intervention: LAmbre Occluder
Description: All patients are implanted with Lifetech LAmbre occluder device.
Study: NCT02531425

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IT-pIL12-EP
Description: Intratumoral pIL-12 injections followed immediately by electroporation into accessible tumor lesions
Study: NCT04088240

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DPA enriched n-3
Description: 4 g/d DPA enriched n-3 concentrate (\~980 mg DPA, 380 mg EPA, 1720 mg DHA)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: n-3 control
Description: 4 g/d n-3 control (\~980 oleic acid, 380 mg EPA, 1720 mg DHA)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 g/d placebo control (light olive oil)
Study: NCT03504540

Intervention type: PROCEDURE
Intervention: Blood test
Description: Blood test for complement factors and genetic polymorphisms of AMD analysis

Intervention type: PROCEDURE
Intervention: Blood test
Description: Blood test for complement factors and genetic polymorphisms of AMD analysis
Study: NCT03969056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence (AI) Activity
Description: The intervention provides participants with an automated and personalized daily step goal intervention involving a sophisticated activity analytics algorithm using advanced statistics and machine learning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 10,000 steps
Description: The intervention provides participants with an automated daily 10,000 step goal intervention
Study: NCT01818739

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node detection
Description: Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green solution
Description: Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isosulfan blue
Description: Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node biopsy
Description: Undergo sentinel lymph node biopsy
Study: NCT04640558

Intervention type: DEVICE
Intervention: Muscle strength measurement
Description: The bilateral gluteus medius muscle strength of each participant will be measured by the assessor (MB) blinded to the participants using the Lafayette manual muscle tester. (Lafayette Instrument Company, Lafayette IN, USA). In the participant's side-lying position, the practitioner applied resistance from the upper ankle to the abduction movement with slight flexion of the upper hip. During the measurements, the participants were asked to perform the maximum isometric contraction for 3 seconds. Gluteus medius muscle strength measurements were repeated three times, one minute apart, on the right and left sides. The mean of the measurements was calculated and recorded

Intervention type: DEVICE
Intervention: Muscle strength measurement
Description: The bilateral gluteus medius muscle strength of each participant will be measured by the assessor (MB) blinded to the participants using the Lafayette manual muscle tester. (Lafayette Instrument Company, Lafayette IN, USA). In the participant's side-lying position, the practitioner applied resistance from the upper ankle to the abduction movement with slight flexion of the upper hip. During the measurements, the participants were asked to perform the maximum isometric contraction for 3 seconds. Gluteus medius muscle strength measurements were repeated three times, one minute apart, on the right and left sides. The mean of the measurements was calculated and recorded
Study: NCT04155086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the detection of the risk of fetal trisomy 21 by blood tests : free fetal DNA circulant analysis
Description: The detection of the risk of fetal trisomy 21 by blood tests by 2 tests : free fetal DNA circulant analysis and first trimester serum screening

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: the detection of the risk of fetal trisomy 21 by blood tests : free fetal DNA circulant analysis
Description: The detection of the risk of fetal trisomy 21 by blood tests by 2 tests : free fetal DNA circulant analysis and first trimester serum screening
Study: NCT01781650

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air Insufflation method.
Description: Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Immersion method.
Description: Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if \>3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Exchange method.
Description: Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
Study: NCT00139542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One shock per minute AED protocol
Description: Single shocks; No post-shock pulse checks; 60 sec CPR before first shock; 30 sec CPR between rhythm analysis and shock delivery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guidelines 2000 AED protocol
Description: Up to 3 consecutive shocks in a stack; No initial CPR prior to the first shock; Post-shock pulse checks after each non-shockable rhythm analysis; 60 sec CPR after each non-shockable rhythm analysis.
Study: NCT04138914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal Cryotherapy
Description: Ablation of the cancer focus within the prostate using cryotherapy
Study: NCT02276352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment 3
Study: NCT01595230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closing the mesenteric defects with clips during opration
Description: The laparoscopic Roux-en-Y gastric bypass surgery will be performed as usual. The patient will receive the closing of the mesenteric defects (the Petersen´s space and the entero-enterostomy site).The closing will happen at the end of the operation, using clips (herniestapler).
Study: NCT02901054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: A single 15-min intravenous infusion of ondansetron
Study: NCT03802305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: computerized intraosseous technique (Quicksleeper™)
Description: The anesthetic solution is administered with a specific equipment allowing the injection step by step:~* anesthesia of the interdental papilla,~* positioning of the needle and perforating of the interdental space,~* Injection of the solution. All of these steps are based on an adjustment of the different part of this equipment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: loco-regional anesthesia (IANB technique)
Description: The anesthetic solution is delivered by a needle near to the inferior alveolar nerve before it enters the mandibular foramen.
Study: NCT04587414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth +counselling contacts
Description: The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. The eHealth intervention is complemented by face-to-face and telephone counselling on physical activity which comprises 4 to 6 contacts between a health care professional and the patient as well as at least 3 telephone contacts during 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth
Description: The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. No telephone calls nor face-to-face counselling contacts on physical activity are taken.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: Usual care and councelling given to type 2 diabetics within the primary health care setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care and councelling given to type 2 diabetics within the primary health care setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care and councelling given to type 2 diabetics within the primary health care setting.
Study: NCT01407471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol + Spironolactone
Description: One application 6 days a week during 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol + Placebo
Description: One application 6 days a week during 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + Spironolactone
Description: One application 6 days a week during 7 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Placebo
Description: One application 6 days a week during 7 weeks
Study: NCT00948233

Intervention type: BEHAVIORAL
Intervention: Video Game
Description: Educational anti-tobacco video game played on arcade-type kiosk for three 30-minute sessions, plus CD-ROM disc of game to use as needed, and series of illustrated materials to go along with computer sessions.

Intervention type: BEHAVIORAL
Intervention: Pamphlet
Description: Self-help pamphlet about stopping and avoiding tobacco use, provided by the National Institutes of Health.

Intervention type: BEHAVIORAL
Intervention: Surveys
Description: Computer surveys taken at 4 points throughout the study.

Intervention type: BEHAVIORAL
Intervention: Surveys
Description: Computer surveys taken at 4 points throughout the study.